[{"address1": "263 Great Valley Parkway", "address2": "Suite 160", "city": "Malvern", "state": "PA", "zip": "19355", "country": "United States", "phone": "484 328 4701", "website": "https://www.ocugen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.", "fullTimeEmployees": 84, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shankar  Musunuri M.B.A., Ph.D.", "age": 59, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 1201460, "exercisedValue": 1257295, "unexercisedValue": 263200}, {"maxAge": 1, "name": "Dr. Uday B. Kompella Ph.D.", "age": 56, "title": "Co-founder & Independent Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 56724, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Breininger CPA, M.B.A.", "age": 41, "title": "Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller", "yearBorn": 1982, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arun  Upadhyay Ph.D.", "age": 40, "title": "Chief Scientific Officer and Head of Research & Development", "yearBorn": 1983, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "John  Kouch J.D.", "title": "General Counsel", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tiffany J. Hamilton M.B.A.", "title": "Head of Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Shine M.B.A.", "title": "Senior Vice President of Commercial", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jyothy  Pillai M.S.", "title": "Head of Regulatory & Quality", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.1, "open": 1.11, "dayLow": 1.1, "dayHigh": 1.25, "regularMarketPreviousClose": 1.1, "regularMarketOpen": 1.11, "regularMarketDayLow": 1.1, "regularMarketDayHigh": 1.25, "beta": 3.68, "forwardPE": -4.428571, "volume": 8410308, "regularMarketVolume": 8410308, "averageVolume": 6097453, "averageVolume10days": 5645900, "averageDailyVolume10Day": 5645900, "bid": 1.22, "ask": 1.29, "bidSize": 100, "askSize": 100, "marketCap": 318062496, "fiftyTwoWeekLow": 0.345, "fiftyTwoWeekHigh": 1.28, "fiftyDayAverage": 0.75766, "twoHundredDayAverage": 0.535885, "currency": "USD", "enterpriseValue": 271062016, "floatShares": 252377875, "sharesOutstanding": 256502000, "sharesShort": 36649164, "sharesShortPriorMonth": 23706525, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.1429, "heldPercentInsiders": 0.014520001, "heldPercentInstitutions": 0.10342, "shortRatio": 4.47, "shortPercentOfFloat": 0.18530001, "impliedSharesOutstanding": 256502000, "bookValue": 0.228, "priceToBook": 5.4385967, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -75524000, "trailingEps": -0.32, "forwardEps": -0.28, "lastSplitFactor": "1:60", "lastSplitDate": 1569801600, "enterpriseToEbitda": -3.373, "52WeekChange": 0.40909088, "SandP52WeekChange": 0.32311738, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "OCGN", "underlyingSymbol": "OCGN", "shortName": "Ocugen, Inc.", "longName": "Ocugen, Inc.", "firstTradeDateEpochUtc": 1417617000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "169c2c50-f570-39a4-b709-68c305b79bbd", "messageBoardId": "finmb_303874231", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.24, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.33, "targetMedianPrice": 7.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 53477000, "totalCashPerShare": 0.208, "ebitda": -80360000, "totalDebt": 6475000, "quickRatio": 4.802, "currentRatio": 5.079, "debtToEquity": 11.088, "returnOnAssets": -0.53069, "returnOnEquity": -0.98276, "freeCashflow": -51908248, "operatingCashflow": -67666000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-21"}]